Clinical trial
Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)
NCT00074529 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00074529 |
|---|---|
| Title | Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED) |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer's Disease |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | MK0677 |
| Enrollment | 512 |
| Start date | Oct 1, 2003 |
| Primary completion | Jan 1, 2006 |
| Completion | Jan 1, 2006 |
| First posted | Dec 16, 2003 |
| Last update posted | Jul 24, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: